A Phase II /III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol. 2018;12:1921–1929. On page 1924, Efficacy end points, Conjunctival staining section, the sentence “Statistically significant reductions in the mean change from baseline in the study eye at Day 84 relative to ve...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/927ca671855946069329c9e9d60abafd |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol. 2018;12:1921–1929. On page 1924, Efficacy end points, Conjunctival staining section, the sentence “Statistically significant reductions in the mean change from baseline in the study eye at Day 84 relative to vehicle were observed for both OTX-101 concentrations (P<0.01). The results by study visit are depicted in Figure 3.” should read “Statistically significant reductions in the least squares mean change from baseline in the study eye at Day 84 relative to vehicle were observed for both OTX-101 concentrations (P<0.01). The results by study visit are depicted in Figure 3.” Read the original article |
|---|